40 results about "Transplant Donors" patented technology

A method of organizing and making available transplant donor data, the method comprising the steps of: (a) providing a secure database to store transplant donor data; (b) providing access to a selective third party to at least one of upload and view transplant donor data and download and view transplant donor data; and (c) generating an authorization code required to access the transplant donor data by the selective third party.

The invention discloses a primer group, a kit and a method for amplification of a human leukocyte antigen-B (HLA)-B gene, and the primer group, the kit and the method for genotyping of the HLA-B gene,belonging to the field of gene detection. According to the primer group, provided by the invention, for the amplification of the HLA-B gene, at least two sets of primers are designed according to theeight exon regions of the HLA-B gene; the primers are used for performing polymerase chain reaction (PCR) amplification on the HLA-B gene, so that a product having a gene fragment length of less than1.5 kb is obtained; after the HLA-B gene is subjected to the PCR amplification by the primers, the gene fragment length of the amplified product is less than 1.5 kb, so that the requirement for template integrity is reduced, the amplification efficiency is high, amplification reaction time is short, and the cost is low. The primer groups, the kits and the methods can meet the needs of amplification or genotyping of the HLA-B gene in mass samples, provide a more accurate basis for clinical HLA matching, provide suitable transplant donors for patients, reduce the rejection in a transplantationprocess and improve the success rate of organ transplantation and the patient survival rate.

Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity. In one embodiment, skin from the transplant donor is allografted to the transplant recipient to induce an immunological response to the transplanted skin. A quantity of blood is taken from the recipient and treated to render the T cells in the blood apoptotic and to induce differentiation of blood monocytes into dendritic cells. The treated blood is incubated and administered to the recipient to induce formation of suppressor T cell clones which reduce the number of T cells attacking the transplanted tissue or organ. This tolerogenic approach can be complemented by also feeding the immature dendritic cells apoptotic or necrotic cells from the organ donor. In a second embodiment, dendritic cells loaded with tumor antigens are injected intradermally to monitor the anti-cancer immunity induced by Transimmunization.

Cell-based compositions and methods of their use to inhibit an adverse immune response such as graft versus host disease or rejection of transplanted tissue in a transplant recipient that is histocompatibility mismatched to the transplant donor are disclosed. The compositions and methods utilize postpartum-derived cells, such as cells derived from the placenta or umbilicus.

The invention relates to a kidney transplant donor-specific urine source cell and its DNA preparation method, and an application in kidney transplant donor genomics background analysis. The preparation method of the urine source cell of the invention comprises the following steps: (1) taking a middle section of urine of a kidney transplant acceptor, centrifuging the material, and discarding a supernatant; (2) adding a phosphate buffer solution containing a penicillin streptomycin mixture or a primary cell antibiotic to a lower layer obtained by centrifugation, performing resuspending, and thencentrifuging the material again, discarding the supernatant; (3) adding a urine source cell culture medium to a lower layer precipitate obtained by centrifugation, and performing resuspending to obtain a cell suspension; and (4) inoculating the obtained cell suspension into a culture vessel, and performing the cell amplification in vitro to obtain the kidney-transplant donor-specific urine sourcecell. The method obtains the donor-specific urine source cell based on kidney transplant postoperative acceptor urine, obtains donor DNA, performs donor genomics background analysis, is safe, non-invasive, low-cost, and highly efficient for separation, and is easy to obtain a sufficient amount of DNA.

The invention relates to a method for preparing a fecal microbiota transplantation capsule containing benzoylaconine by utilizing human fecal microbiota fermented aconite roots. Fecal microbiota transplantation (FMT) means that a functional flora in healthy human feces is transplanted into gastrointestinal tracts of a patient to re-establish a new intestinal flora so as to realize treatment on intestinal and parenteral diseases. Clinical application discovers that a required curative effect cannot be achieved after certain patients take the prepared aconite roots, one of main reasons causing individual differences is incomplete intestinal flora of the patient, and toxic substances in the prepared aconite roots cannot be normally metabolized into non-toxic active ingredients, the active ingredients have low utilization, and the required curative effect of the prepared aconite roots cannot be achieved. Healthy high-quality feces of a fecal microbiota transplant donor are utilized, are used for simulating intestinal microbes in vitro to achieve an effect of transforming the prepared aconite roots, aconitine and other toxic ingredients in the prepared aconite roots can be transformed into nontoxic metabolitic products through proper fermentation conditions, and the content of benzoylaconine and other active ingredients is increased. The fecal microbiota capsules prepared from fecalmicrobiota fermentation liquid can be used in fecal microbiota transplantation treatment in clinical application.

The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.

Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity. In one embodiment, skin from the transplant donor is allografted to the transplant recipient to induce an immunological response to the transplanted skin. A quantity of blood is taken from the recipient and treated to render the T cells in the blood apoptotic and to induce differentiation of blood monocytes into dendritic cells. The treated blood is incubated and administered to the recipient to induce formation of suppressor T cell clones which reduce the number of T cells attacking the transplanted tissue or organ. This tolerogenic approach can be complemented by also feeding the immature dendritic cells apoptotic or necrotic cells from the organ donor. In a second embodiment, dendritic cells loaded with tumor antigens are injected intradermally to monitor the anti-cancer immunity induced by Transimmunization.

The invention relates to a medical forming device for a gristle transplanting receptor spongy bone bed. Multiple knife edges are connected to a knife head base connected with a knife head connecting rod through a universal ball joint. The knife head connecting rod is connected with a handle connecting rod and a handle, the handle is connected with a handle stopping block, and the handle stopping block is connected with a manual sliding impacting device or an electric impacting device. The defects that in the prior art, because a bone knife, a bone chisel and other simple tools are used for manually trimming, the bone cutting face is not flat, randomness is high, and the bone cutting face of a receptor and the bone cutting face of a donor are prone to being mismatched, which is adverse to bone healing are overcome. The receptor spongy bone bed can be formed through one-off impacting, so that forming efficiency is improved, operation time is shortened, and the form of the receptor spongy bone bed is kept uniform. The manual sliding impacting device and the electric impacting device can be selected for use, so that the form of the spongy bone, after cutting, below the transplanted donor gristle is completely matched with that of the receptor sponge bone bed, a transplanted donor and a receptor are completely matched, and bone healing is facilitated.

The present invention relates to a gas delivery device comprising a gas releasing molecule and a gas permeable membrane. The invention also relates to the use of the gas delivery device for delivery of gas to an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff and in therapy. The invention further relates to the use of a gas permeable and liquid and solid impermeable membrane to separate a gas releasing molecule and its non-gaseous degradation products from an extracorporeal transplant, extracorporeal cells, a brain-dead transplant donor or foodstuff.

The present invention relates to the identification of single nucleotide polymorphisms (SNPs) in the gamma genomic block of the central region of the major histocompatibility complex (MHC), which can be used to match transplant donors and recipients and determine disease susceptibility. emotional.

Provided are compositions and methods for donor selection and prognosis of acute graft-versus-host disease. Provided is a method, which comprises obtaining a first biological sample from a first subject at risk of GVHD; detecting a level of miR-142-3p in the sample; and determining a risk of, prognosis of, or diagnosis of GVHD in the first subject. Provided also is a method for selecting a stem cell transplant donor, which comprises obtaining a first biological sample from a first subject and a second biological sample from a second subject, detecting a level of miR-142-3p in the first biological sample and the second biological sample; determining a ratio of the level of miR-142-3p in the second biological sample to the level of miR-142-3p in the first biological sample; determining the likelihood of the first subject will develop GVHD based on the ratio; and selecting a transplant donor based on the ratio.